Bharat Biotech
-
BHU study: Over 30 per cent of Covaxin recipients report adverse events
India | May 16, 2024, 11:41 PM ISTThe one-year follow-up study, involving 926 participants, highlighted the long-term safety of the BBV152 vaccine, with serious adverse events like stroke and Guillain-Barre syndrome reported in one percent of recipients.
-
COVID-19: 3 lakh doses of intranasal vaccine 'iNCOVACC' sent to hospitals, informs Bharat Biotech
India | Feb 05, 2023, 06:29 PM ISTCOVID-19 vaccine: iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26 (Thursday). The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.
-
What is nasal vaccine - iNCOVACC? All you need to know
Health | Jan 27, 2023, 01:15 PM ISTCovid19 nasal vaccine: The nasal vaccine was launched on the occasion of the 74th Independence Day to the public in the national capital by Union Health Minister Mansukh Mandaviya.
-
First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26
India | Jan 21, 2023, 08:11 PM ISTBharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month to sell the nasal vaccine in India. The vaccine is also available on the CoWIN platform.
-
Bharat Biotech's nasal vaccine for Covid to cost Rs 800 for private hospitals, Rs 325 for govts
India | Dec 27, 2022, 01:11 PM ISTThe nasal vaccine, iNCOVACC, which will be rolled out in the fourth week of January is for those above 18 years of age. The slots for the vaccine can now be booked on CoWin's portal.
-
Centre rejects media reports claiming approval for Covaxin rushed due to political pressure
India | Nov 17, 2022, 02:46 PM ISTThe government said the scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization.
-
COVID: 50 million Covaxin doses set to expire due to poor off take
India | Nov 06, 2022, 01:41 PM ISTCovaxin news: “Covaxin doses in vials are set to expire during early 2023, resulting in losses for the company,” said sources.
-
Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval
India | Sep 06, 2022, 03:37 PM ISTThis will be India's first nasal vaccine for COVID-19. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19.
-
Japan has approved Covaxin booster dose for travellers: Bharat Biotech
India | Aug 05, 2022, 10:56 PM ISTIn April this year, the Japanese government announced including Covaxin in its list of recognized vaccines to further facilitate travel from India.
-
Bharat Biotech's COVID-19 nasal vaccine phase III trials completed
India | Jun 19, 2022, 06:54 AM ISTKrishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.
-
Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech
India | Jun 17, 2022, 12:25 PM ISTA press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.
-
Germany recognises Bharat Biotech's Covaxin for travel from June 1
India | May 26, 2022, 12:07 PM ISTThe DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.
-
COVID vaccination: DCGI asks Bharat Biotech to provide more data on Covaxin for below 12-year-olds
India | Apr 22, 2022, 02:09 PM ISTThis development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.
-
Bharat Biotech to soon rectify issues raised by WHO on Covaxin, say sources
India | Apr 05, 2022, 06:58 AM ISTRecently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."
-
Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies
India | Apr 04, 2022, 10:10 AM ISTEarlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
-
No impact on efficacy and safety of Covaxin: Bharat Biotech after WHO suspension
India | Apr 03, 2022, 09:48 AM ISTThe vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.
-
Bharat Biotech says slowing down Covaxin production for facility optimisation
India | Apr 01, 2022, 11:20 PM ISTThe company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
-
Bharat Biotech gets approval for intranasal Covid-19 booster dose trials
India | Jan 28, 2022, 03:56 PM ISTAn intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.
-
Covaxin now universal vaccine for adults, children: Bharat Biotech
India | Jan 14, 2022, 07:26 AM ISTEarlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
-
Covaxin booster dose neutralises Omicron, as well as Delta variants, says Bharat Biotech
India | Jan 12, 2022, 06:26 PM ISTCovaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.